Fintel reports that on April 1, 2025, HC Wainwright & Co. initiated coverage of Rezolve AI (NasdaqGM:RZLV) with a Buy ...

H.C. Wainwright analyst Ed Arce raised the firm’s price target on Unicycive Therapeutics (UNCY) to $7.50 from $4 and keeps a Buy rating on the ...

HC Wainwright cut their FY2028 EPS estimates for shares of Gevo in a report released on Friday, March 28th. HC Wainwright ...

Fintel reports that on March 31, 2025, HC Wainwright & Co. initiated coverage of Virax Biolabs Group (NasdaqCM:VRAX) with a ...

H.C. Wainwright analyst Scott Buck initiated coverage of Rezolve AI (RZLV) with a Buy rating and $4 price target Rezolve AI develops and ...

Stock analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for shares of Acumen Pharmaceuticals ...

Virax Biolabs' T-cell testing platform targets post-viral syndromes like Long COVID. HC Wainwright sees a major market opportunity, setting a $3 price target.

Despite a major shift toward Bitcoin losing 10% of its value since the start of the year.

Investors with a lot of money to spend have taken a bearish stance on Corcept Therapeutics CORT. And retail traders should ...

Surf Air Mobility Inc. (NYSE: SRFM) (the "Company"), a leading regional air mobility platform, closed on the previously announced purchase and sale of 2,000,000 shares of common stock (or pre-funded ...

H.C. Wainwright analyst Joseph Pantginis raised the firm’s price target on Aptose Biosciences (APTO) to $6 from $2 and keeps ...